Innate Pharma
IPH
EUR
STOCK MARKET:
EPA
Open
 
...
Large gap with delayed quotes
Last quote
04/16/2026 - 13:28:56
1.44
+0.03 ( +2.13% )
More information
Analysis by TheScreener
14.04.2026
Evaluation Slightly negative  
Interest Strong  
Sensibility High  
Analysis date: 14.04.2026
Global Evaluation
  Slightly negative
The stock is classified in the slightly negative zone since 14.04.2026.
Interest
  Strong
Three stars since 14.04.2026.
Earnings Rev Trend
  Positive
 
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 07.04.2026 at a price of 1.10.
Evaluation
  Strongly overvalued
 
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
  Positive
 
The dividend-adjusted forty day technical trend is positive since 14.04.2026.
4wk Rel Perf
  4.76%
 
The four-week dividend-adjusted overperformance versus STOXX600 is 4.76%.
Sensibility
  High
The stock has been on the high-sensitivity level since 27.03.2026.
Bear Market Factor
  High
On average, the stock has a tendency to amplify the drops in the index by 1.28%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 3.19%.
Mkt Cap in $bn
  0.13
With a market capitalization <$2bn, INNATE PHARMA is considered a small-cap stock.
G/PE Ratio
  0.52
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
  -2.82
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
  1.48%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
  4
Over the last seven weeks, an average of 4 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  157
For 1% of index variation, the stock varies on average by 1.57%.
Correlation
  0.41
41.48% of stock movements are explained by index variations.
Value at Risk
  0.69
The value at risk is estimated at EUR 0.69. The risk is therefore 50.49%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  08.04.2014